Key facts
- It has raised $14.0M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Lanchi Ventures, SAIC Capital China, Jinding Capital, BioTrack Capital, Huagai Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Aphranel
- ·The full record, as it builds
Funding rounds
No funding rounds for Aphranel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aphranel
Developer of medical biomaterials designed for medical beauty. The company's products mainly focus on nanomedical biomaterials and three types of absorbable implant products, which can be applied in the medical beauty industry. The products contain recombined type III collagen, which can promote epidermal cell regeneration and accelerate skin barrier repair, providing customers with safe and effective products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- aphranel.com/
- Ownership
- Privately Held (backing)
Aphranel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aphranel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aphranel in its N-PORT filings yet. We sweep new filings monthly.